0000000000882269

AUTHOR

Andrea Parisini

showing 4 related works from this author

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Abstract Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years). Results In 1394 subjec…

Cross-Sectional StudieMaleART exposureHIVMultimorbidityHIV InfectionsComorbidityOsteoporosis.Noncommunicable DiseaseBone Diseases MetabolicCross-Sectional StudiesInfectious DiseasesAgeAnti-Retroviral AgentsHypertensionHumansOsteoporosisAnti-Retroviral AgentFemaleHIV InfectionNoncommunicable DiseasesAgedHuman
researchProduct

Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".

2022

Dear Editor, Elhence et al.1 assessed the retreatment outcomes of direct‐ acting antivirals (DAAs) therapy failure in a cohort of 40 patients with chronic hepatitis C (HCV) and previous virological failure (VF) to DAAs. The results were remarkable, with an overall sustained virologic response (SVR) of 100% in patients who completed retreatment with sofosbuvir and velpatasvir (with/without ribavirin). We compared these results with our experience in the multicenter HCV‐ Surveillance Cohort Long‐Term Toxicity Antivirals (HCV‐SCOLTA) cohort, an active pharmacovigilance system supported by the CISAI group (Italian Coordinators for the Study of Allergies and HIV Infection). Since 2012, Italian i…

MaleAntiviral agentSustained Virologic ResponseAnti-hepatitis C virus DAA (directly acting antivirals); Antiviral agents; Hepatitis C virus; Hepatitis virus; Virus classification; Antiviral Agents; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Medication Adherence; Middle Aged; Sustained Virologic ResponseHepatitis C virusTreatment outcomeHepacivirusmedicine.disease_causeAntiviral AgentsHepatitis viruMedication AdherenceChronic hepatitisVirologyMedicineHumansIn patientChronicAnti-hepatitis C virus DAA (directly acting antivirals)Virus classificationHepatitis virusVirus classificationHepatitis C virusbusiness.industryAntiviral therapyHepatitis C ChronicMiddle AgedHepatitis CVirologyHepatitis virusInfectious DiseasesItalyFemaleHepatitis C virubusinessDirect actingJournal of medical virology
researchProduct

Analysis of Σ=3 and Σ=9 Twin Boundaries in Three-Crystal Silicon Ingots

1995

CrystalMaterials scienceSiliconchemistryCondensed matter physicschemistry.chemical_elementGeneral Materials ScienceCondensed Matter PhysicsAtomic and Molecular Physics and OpticsSolid State Phenomena
researchProduct

Additional file 1 of Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Additional file 1: Table S1. Comorbidities by age class (%), comparison with the general Italian population.

researchProduct